派格生物首个产品获批,GLP-1赛道已有16个玩家;复宏汉霖HLX43启动II期临床,适应证为胰腺导管腺癌 | 掘金创新药

每日经济新闻
Nov 19

一周行情  11月10日至11月14日,医药生物指数上涨2.19%,跑赢上证指数2.65个百分点,结束近2个月的低迷行情。创新药(BK1106)周内上涨4.93%;恒生医疗保健业指数(HSCICH)周内上涨7.18%;港股创新药ETF(513120)周内上涨5.90%。  一周点评  上周医药板块结束调整强势反弹,创新药及港股医疗表现尤为亮眼,显示市场对政策担忧有所缓解,风险偏好显著回升。当前医药...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10